Kylonova (Xiamen) Biopharmaceutical Co., Ltd. (Abbr.: Kylonova ) is mainly engaged in the research and development of new siRNA (small interfering nucleic acids) drugs and delivery platforms. The company has discovered three siRNA delivery platforms with full intellectual proprietary, including Nano-Lipid Particle Delivery Platform(NPDP), Multi-Valent Import Platform(MVIP) and  Lipid-Coupling Delivery platform(LCDP). The technologies and quality standards for three delivery platforms are leading in the related fields, scalable and commercializable. Kylonova also performs solid phase oligonucleotide synthesis for API production of DNA and RNA and contract manufacturing.

 Based on the established platforms, Kylonova is currently focusing on the development of RNAi therapeutics for liver-related diseases such as chronic hepatitis B (HBV), hepatic carcinoma and non-alcoholic fatty liver disease (NAFLD). Kylonova is led by a team of overseas scientists in this field with more than 30 patents/patent applications, 18 of which have been approved. These patents cover the compounds, uses, preparation processes and formulation compositions and prescription etc.